Mary Tanner is a Senior Managing Director of EVOLUTION Life Science Partners, an investment banking and advisory boutique, offerings securities through Gordian Investments, LLC, Member FINRA/SPIC.
Ms. Tanner is also a co-founder, with Frederick Frank, of Life Sciences Partners, LLC, a financial advisory and consulting firm. Life Sciences Partners concentrates on strategy and financial advice to life sciences companies. Previously, she served as Senior Managing Director at Lehman Brothers Inc. and Bear Stearns & Co., and as a Managing Director of Peter J. Solomon Company.
Ms. Tanner has devoted more than 25 years to the global healthcare industry. Her expertise includes the ethical pharmaceutical industry, biotechnology, diagnostics, medical devices, healthcare services, cosmetics and consumer medicine industries. In addition to her well-known work with large companies, Ms. Tanner specializes in domestic and cross-border transactions between large and small companies, including corporate partnering and minority investments.
Ms. Tanner’s clients have included: Pfizer in its $60 billion acquisition of Pharmacia; Amgen in its $16 billion acquisition of Immunex; Rhône-Poulenc in its acquisition of Rorer; followed by Rhône-Poulenc Rorer in its acquisition of U.K. company Fisons; BASF/BASF Pharma, in its acquisition of U.K. company Boots Pharmaceuticals and numerous other strategic transactions. Ms. Tanner has directed over 130 initial public offerings of life sciences companies.
Ms. Tanner received a B.A. from Harvard University. Ms. Tanner is a member of the Board of Directors of Lineagen, Inc., a molecular diagnostics company and Genticel SA, an immune oncology company. She serves on the Dean’s Council of the Yale School of Medicine and the Advisory Board of the Yale School of Management.